# Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

> **NCT00120939** · PHASE1 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 25 (—)

## Conditions studied

- Breast Neoplasms
- Ovarian Neoplasms
- Prostatic Neoplasms
- Lung Neoplasms
- Gastrointestinal Neoplasms

## Interventions

- **DRUG:** Motexafin Gadolinium

## Key facts

- **NCT ID:** NCT00120939
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 25 (—)
- **Last updated:** 2009-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00120939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00120939, "Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00120939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*